Full-Year Report 2009 <

http://hugin.info/133973/R/1389812/347933.pdf>


  * Multiple approvals and launches: Cimzia® for RA in the U.S. and EU, Vimpat®
    for epilepsy in the U.S. and in the EU, Neupro® for new patients in
    Parkinson's disease and RLS in the EU
  * Total revenue decreased as expected by 13% to EUR 3.1 billion due to the
    full-year impact of generic competition to Keppra® in the U.S. and
    divestitures
  * Strong underlying profitability (recurring EBITDA) of EUR 698 million (-5%)
    well in line with company guidance (more than EUR 680 million) and
    reflecting the significant impact of generic competition to Keppra® in the
    U.S., mostly compensated by lower operating expenses as a result of UCB's
    focus on its core activities
  * Net profit after minorities increased to EUR 513 million in 2009 from
    EUR 42 million in 2008, reflecting higher non-recurring income stemming from
    capital gains and overcompensating non-recurring charges relating to the
    debt refinancing and organizational changes
  * Increased gross dividend of EUR 0.96 per share recommended by Board of
    Directors
  * Outlook 2010: total revenue expected to reach approximately EUR 3.0 billion;
    underlying profitability (recurring EBITDA) expected to end the year at
    approximately  EUR 700 million; Core EPS (earnings per share) expected to
    reach approximately EUR 1.76


Brussels (Belgium), 2 March 2009 - 7:00 AM (CET) - regulated information - UCB
announced today its consolidated full year 2009 financial results. 2009 was a
year of execution and delivery. The company reached a turning point through new
drug approvals and launches as well as the transformation of its organization.
UCB achieved major development and regulatory milestones and reduced and
refinanced the existing debt with a new financing structure reflecting an
improved maturity profile. With all this, UCB created a strong basis for
sustainable future growth.

"UCB is progressing to become a patient-centric global biopharmaceutical leader
as we delivered three new medicines Cimzia®, Vimpat® and Neupro® in five
indications to patients living with serious diseases of the central nervous
system and immunology. Our financial results are on track and our debt is
successfully re-financed. Another pillar of UCB's sustainable growth will be the
realization of the full potential of our core products: Cimzia®, which we expect
to reach peak sales of at least 1.5 billion Euro, Vimpat® with expected peak
sales of at least 1.2 billion Euro and Neupro® with estimated peak sales of at
least 400 million Euro," said Roch Doliveux, Chief Executive Officer, UCB. "With
the recent appointment of Ismail Kola as Executive Vice President, UCB &
President of UCB NewMedicines(TM), we have underlined our commitment to a
successful breakthrough phase bringing new medicines to the development pipeline
and fostering further sustainable growth."


The full press release can be downloaded from the following link:



[HUG#1389812]





    Full-Year Report 2009: 

http://hugin.info/133973/R/1389812/347933.pdf